Targeting Cancer Screening

Seiwa Genetics and the field of clinical grade gene sequencers

Leading enterprise UWI

Strategic cooperation for globalization

Mou Feng, Chief Executive Officer of UWI, and Shao Yang, Founder, Chairman and Chief Executive Officer of Shihe Genetics, signed the cooperation agreement on behalf of the two parties respectively.

Ltd. is one of the few companies in the world that can independently develop and mass produce clinical grade gene sequencers with different throughputs from Gb grade to Tb grade low, medium and high.With operations in more than 100 countries and territories on six continents, it is a leading company in the life sciences and biotechnology sector.

Nanjing Shihe Gene Biotechnology Co., Ltd. is the leader of tumor NGS technology in China.Key technological breakthroughs have been achieved in precision tumor diagnosis and early screening, and two major innovative medical devices have been approved by the State Drug Administration for marketing.Previously, Shiho Genetics had carried out tumor-related product development based on several sequencing platforms of UWI.

Under the agreement, the two companies will jointly empower the Jinling Cohort, a large-scale prospective natural population-based early tumor screening programWe will provide technical support for the development of early tumor screening in China, lead the industry in compliance, and promote more breakthroughs in the clinical translational application of high-throughput sequencing technology in oncology by complementing each other's technological advantages.

In 2022, Jiangbei New Area and Shiho Genetics joined hands to create a public welfare program for early tumor screening, "Jinling Queue", based on Shiho Genetics' self-developed technology for early tumor screening, to provide continuous medical checkups and early tumor screening services for the citizens in the area.Up to now, the program has provided appropriate services to 15,000 Nanjing citizens.

The strong alliance between Shihe Genetics and UWI will further accelerate the clinical transformation of scientific and technological innovation and cutting-edge achievements, reduce the cost of testing, enhance the efficiency of services, and help the development of tumor precision medicine towards high quality and standardization.

Mou Feng, CEO of UWI, said he hopes to bring more cutting-edge and cost-effective empowerment to Shihe Genetics based on the cost advantages and broad compatibility of the UWI platform, and to bring breakthrough applications in the field of oncology precision medicine.

In the future, the two sides will focus on key areas such as basic clinical research, registration and certification of instruments and reagents, clinical application and promotion, precision medical treatment of tumors, and early screening and diagnosis of cancer.Based on the hardware support of UW Smart Gene Sequencing Platform, Laboratory Automation Platform, Information Management Platform, etc., it creates an innovative base for tumor precision medicine.

In addition, the two sides will also work together to realize the deep integration of technology and application in the areas of technology R&D and innovation, product and service development, global market expansion and branding, industry policy research and standard setting, and international cooperation and exchange.

In the future vision of Shiho Genetics and UWI, the creation of an industrial ecology has been placed in an important position.In fact, in the new area of biomedical industry main position in the biomedical valley, a characteristic life and health of the whole industry chain innovation system has been initially formed.One of the leading industries is the gene and cell industry, where many technology-based teams like Shiho Genetics are gathering, developing and growing.

For example, Zenmax Bio, which focuses on the R&D and manufacturing of gene sequencers, has landed in the new area for a year and is about to launch new products, and is currently stepping up preparations for the product launch; Senta Bio, which has long been deeply engaged in the field of glycomics, has independently researched and developed China's first auxiliary diagnostic product for tumors based on glycomics technology, and not long ago, it took the certificate of registration of Class III medical device from the State Pharmaceutical Administration of China, and has been approved for market launch. ...... When the excellent enterprises gather into a momentum, more and more good news on the industry chain will come one after another.